← All trials
NCT07164183
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 11, 2025
- Primary completion
- Oct 31, 2026
- Completion date
- Nov 30, 2026
- First posted
- Sep 10, 2025
- Last posted
- Sep 18, 2025
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AlceaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.